Skyrizi · Psoriasis · Commercial
modeled path branch not taken● favorable outcome● denial● conditional / time-limited● do at the same time — parallel track
Documentation packet
“Documentation is not just clinical — it is access.” — Improving the Patient Journey §8
Treatment history
0 completeTick what the patient has tried, then add duration, outcome and why it stopped. “Failed topical steroids” is not enough. Therapies from years ago still count.
Topical corticosteroid
Systemic therapy
Generated for the chart
— tick a therapy above —
Insider movePhototherapy counts as a systemic step in most plans and is far easier to document than a methotrexate trial. If the patient can't get to a box, say so explicitly — distance and access are accepted contraindications.
Enroll at step 2
parallel trackDo this at step 2, not at the endSend the enrollment the same day as the PA. The patient gets medication sooner, and some manufacturers limit bridge eligibility when enrollment is late.
- Hub
- Skyrizi Complete
866-759-7494 - Form
- Skyrizi Enrollment Form, or enroll on CompletePro
- Fax
- 1-678-727-0690
Bridge — enrolled now, activates laterSkyrizi Bridge. Enrollment is on file from step 2; the bridge activates after PA denial and appeal submission.
Send with the enrollment
Step therapy & program terms
Psoriasis- Topical corticosteroid — clobetasol, triamcinolone or betamethasone
- Systemic therapy — methotrexate, phototherapy or cyclosporine
- Follow-up at 3 months to document improvement
Bridge triggerSkyrizi Bridge — After PA denial and appeal submission. Runs up to 2 years, sustained.
Program noteComplete Pro back-up fax 678-727-0494.
Routing & contacts
unverified- Manufacturer
- AbbVie
- Hub / support
- Skyrizi Complete
866-759-7494 - PAP
- AbbVie Patient Assistance Program
800-222-6885 - PAP fax
- 866-250-2803
- Pharmacy
- Pharmacy Solutions (AbbVie)
Copay cardCommercial plan — copay assistance available. Patient cost $5 per fill once approved.
Biosimilars & alternatives
No biosimilar is marketed for Skyrizi (risankizumab-rzaa).
EnbrelNot in the practice's therapy set. Etanercept biosimilars are approved, not launched in the US — not currently a switch option.
If PAP is not an option
Changing therapy is a provider decision. Other therapies for Psoriasis in the reference pack, alphabetical and not ranked:
Medical necessity language
previewCorpus preview — not yet wiredIn the built tool this block comes from /v1/ground, so the medical-necessity paragraph cites attributable expert consensus with KOL, conference and date, filtered to independent sources. Illustrative shape below.
“Systemic therapy is indicated for this patient given documented moderate-to-severe disease with IGA 3–4 and failure of the therapies documented above. Skyrizi is established standard of care for this indication…”
▸ cited from N independent presentations, YYYY–YYYY
▸ consensus: established · KOL count: N
▸ every assertion links to a named speaker, meeting and date
▸ consensus: established · KOL count: N
▸ every assertion links to a named speaker, meeting and date
Usage events this tool reports
0 events
No events yet.